BioCentury | Sep 12, 2019
Preclinical News

Sept. 12 Preclinical Quick Takes: Stephen Quake newco reveals epigenomic platform; plus Personal Genome, Summit and Biolife4D

Bluestar’s epigenomic platform IDs breast, pancreatic cancer Bluestar Genomics Inc. (San Francisco, Calif.) showed it correctly identified breast and pancreatic cancers with areas under the curve of 0.89 and 0.95, respectively, with its machine learning...
BioCentury | Nov 27, 2014
Financial News

S1 Biopharma amends IPO

...the first study by YE15. Lorexys is an oral fixed-dose enteric formulation of bupropion and trazodone...
BioCentury | Oct 24, 2014
Financial News

S1 Biopharma sets IPO range

...next year of lead candidate Lorexys , an oral fixed-dose enteric formulation of bupropion and trazodone...
BioCentury | Oct 2, 2014
Financial News

S1 Biopharma files for IPO

...The biotech's lead product is lorexys , an oral fixed-dose enteric formulation of bupropion and trazodone...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

...CVS Delzicol mesalamine Actavis CVS Anticholinergics (COPD) Tudorza Pressair aclidinium bromide Almirall/Forest CVS Antidepressants Oleptro trazodone...
BioCentury | Aug 5, 2013
Clinical News

Lorexys: Phase IIa started

...Genitourinary Molecular target: NA Description: Oral fixed-dose enteric formulation of a combination of bupropion and trazodone...
BioCentury | Aug 29, 2011
Company News

Labopharm, Angelini deal

...The JV was formed in May 2010 to market major depressive disorder (MDD) drug Oleptro trazodone...
...royalties on net quarterly sales of Oleptro over $10 million in the U.S. In 1Q11, Oleptro...
...for Oleptro. In June, the JV reduced the sales force by 65 (50%) to 65. Oleptro...
BioCentury | Aug 22, 2011
Company News

Labopharm, Paladin deal

...subject to approval by Labopharm shareholders. Business: Neurology Labopharm's pipeline includes two marketed compounds: Oleptro trazodone...
...MOR) agonist and monoamine reuptake inhibitor for pain. Labopharm co-developed and has rights to commercialize Oleptro...
BioCentury | Jul 4, 2011
Company News

Labopharm, Angelini neurology, drug delivery news

...Angelini, Angelini Labopharm, reduced its U.S. sales force for major depressive disorder (MDD) drug Oleptro trazodone...
...ex-European territories under a deal with Angelini. Labopharm recognized $454,000 in revenue from sales of Oleptro...
...May, Labopharm said it entered into discussions with Gruppo Angelini to restructure their deal for Oleptro...
BioCentury | May 9, 2011
Company News

Labopharm, Angelini deal

...discussions with Gruppo Angelini to restructure their deal covering major depressive disorder (MDD) drug Oleptro trazodone...
...in the U.S. through their JV, Angelini Labopharm. Labopharm co-developed and has rights to commercialize Oleptro...
...ex-European territories under a deal with Angelini. Labopharm recognized $454,000 in revenue from sales of Oleptro...
Items per page:
1 - 10 of 53